

### Key Investor Information Document

This document provides you with key investor information about this fund. It is not marketing material. The information is required by law to help you understand the nature and the risks of investing in this fund. You are advised to read it so you can make an informed decision about whether to invest.

# Polar Capital Future Healthcare

(the "Fund"), a sub-fund of Premium Selection UCITS ICAV (the "ICAV")

Class: A dis USD (ISIN: IE00BNGJL194)

This Fund is managed by Three Rock Capital Management Limited (the "Manager"), a wholly owned subsidiary of Julius Baer Group AG

## **OBJECTIVES AND INVESTMENT POLICY**

**Objective:** The Fund aims to preserve capital and achieve long term capital appreciation, by investing in a globally diversified portfolio of companies within the healthcare sector.

companies within the healthcare sector. **Policy:** The Fund invests directly or indirectly up to 100% of its Net Asset Value (and typically at least two thirds of its Net Asset Value) in equities and equity related securities of healthcare companies worldwide, which may be listed on a Regulated Market or unlisted. The Fund may invest up to 10% of its Net Asset Value in global listed securities other than healthcare related companies and up to 30% of its Net Asset Value in ancillary liquid assets and cash. The total amount of these investments is limited to a third of the Fund's Net Asset Value. Up to 30% of its Net Asset Value may be invested in emerging markets. The Fund may invest up to 20% of its Net Asset Value in equity warrants, up 20% of its Net Asset Value in Depositary Receipts (including ADRs, EDRs and/or GDRs) and up to 10% of its Net Asset Value in participatory notes. The Fund can invest directly or indirectly up to 20% of its Net Asset Value in China A shares via both, the Shanghai-Hong Kong Stock Connect or the Shenzhen-Hong Kong Stock Connect and China H-shares traded on the Hong Kong Stock Exchange. The Fund may use financial derivatives for efficient portfolio Exchange. The Fund may use financial derivatives for efficient portfolio management and/or hedging purposes. The Fund may use investment techniques known as 'hedging' to provide protection against exchange risks for the efficient management of its investments or to hedge a non-base currency share class. Such techniques may include options, forwards, futures, swaps and securities lending agreements. The Fund

### **RISK AND REWARD PROFILE**

The synthetic risk reward indicator (the SRRI) rating shows what risk and reward characteristics the Fund has, based on the Fund's historical performance over the last 5 years. Where a 5-year performance history is not available, the history has been simulated on the basis of representative data.

Lower Risk					Higher Risk			
	Typically	Lower Re	wards		Турі	cally Highe	er Rewards	
	1	2	3	4	5	6	7	

On a scale of 1 (less risky) to 7 (more risky), this Share Class has a rating of 6 due to its past performance (or representative data) and the nature of its investments. Shares with a rating of 6 are subject to high price fluctuations.

Risk is taken in order to make a higher potential return; the more risk a fund takes, the higher the potential return but the greater the risk of loss. This indicator is based on historical data and may not be a reliable indication of the future risk profile of the Fund. The risk category shown is not guaranteed and may change over time. The lowest category does not mean risk free.

The Fund does not offer the investor a guaranteed return. Nor does it guarantee the fixed repayment of the money invested in the Fund by the investor.

The indicator takes account of those risks which are entailed in the Fund's net asset value. These mainly involve fluctuations in the value of

may be leveraged up to 100% of the Fund's NAV. The Fund may invest up to 10% of its Net Asset Value in other collective investment schemes. Benchmark: MSCI AC World Daily Total Return Net Health Care USD Index

Benchmark purpose: Performance comparison only. The Fund is actively managed and the Investment Manager has broad discretion to actively managed and the investment Manager has broad discretion to deviate from the Benchmark's constituents, weightings and risk characteristics within the Fund's Objective and Investment Policy. Equities are selected using a stock selection process to generate a high conviction portfolio participating in specific themes which are identified as the future of healthcare, namely, future medicines and technologies, new markets, healthcare delivery, prevention and outsourcing.

Investors may buy and sell shares of the Fund on any bank working day in Ireland (except days where retail banks in New York or London and/or the London Stock Exchange and/or the New York Stock Exchange are closed for holidays).

This share class normally pays an annual dividend based on reportable income.

investment horizon and it may not be appropriate for investors who plan to withdraw their money within five years. For further information, please see the "Investment Objective" and "Investment Policy" sections of the Fund's Supplement.

investments. In addition to the risks expressed through the indicator, the Fund's net asset value may also be significantly affected by the following factors

Market Volatility: The value of the Fund and any income from it can fall or rise because of movements in stockmarkets, currencies and interest rates, each of which can move irrationally and be affected unpredictably by diverse factors, including political and economic events.

Concentration Risk: Investment risk within the Fund is concentrated in specific sectors, countries, currencies or companies. This means the Fund is more sensitive to any localised economic, market, political or regulatory events.

**Derivatives:** The Fund may invest in financial derivative instruments which can result in greater fluctuations of the Fund's value and may cause the Fund to lose as much as or more than the amount invested.

**Currency:** The Fund can invest in other currencies. Changes in exchange rates will therefore affect the value of the investment.

Emerging Markets: The Fund may be invested in emerging market assets. Emerging markets generally carry greater political, legal, counterparty and operational risk. In exceptional circumstances the Fund may encounter difficulties when buying and selling these investments.


For further information on risks, please refer to the Risk Factors section in the Funds prospectus and supplement.

# CHARGES

The charges are used to pay the costs of running the Fund, including the costs of marketing and distributing it. These charges reduce the potential growth of your investment.

One-off charges taken before or after you invest				
Entry charge	5.00%			
Exit charge	3.00%			
This is the maximum that might be taken of your money before it s invested or before proceeds of your investments are paid out.				
Charges taken from the fund over a year				
Ongoing charges	1.55%			
harges taken from the fund under certain specific conditions				
Performance fee	0.00%			

# PAST PERFORMANCE



The entry and exit charges shown are the maximum you will need to pay. In some cases you might pay less - you can find out the actual entry and exit charges from your financial adviser or distributor.

The ongoing charges figure shown here is an estimate of the charges based on a projection of the expenses of the Fund for the first twelve months of operation of the Fund. This figure may vary from year to year. It excludes portfolio trade-related costs, except costs paid to the custodian and any entry/exit charge paid by the fund when buying or selling units/shares in another collective investment undertaking (if any).

A switching charge of up to a maximum of 1.00% of the NAV may be applied.

You will find more details about the calculation of the charges by checking the respective part of the prospectus and of the relevant supplement.

- Past performance is not a guide to future performance.
- The chart shows the Fund's annual performance in USD for each full calendar year over the period displayed in the chart. It is expressed as a percentage change of the Fund's net asset value at each year-end.
- Performance is shown after deduction of ongoing charges. Any entry or exit charges are excluded from the calculation.
- The Fund was launched in April 2021.
- The share class was launched in April 2021.

## **PRACTICAL INFORMATION**

- **Depositary:** The Bank of New York Mellon SA/NV, Dublin Branch (Ireland).
- Further information: Additional information about the Fund (including the prospectus, supplement, latest annual and semiannual reports, as applicable) can be obtained free of charge in English, German, Italian and French, as applicable, upon request to the registered office of the Manager: Three Rock Capital Management Limited, 61 Thomas Street, Dublin 8, Ireland, or by visiting www.fundinfo.com. You can also obtain any of these documents from the representative in your country, where one has been appointed.
- **Price Publication:** The latest share price is published at www.fundinfo.com.
- **Tax legislation:** The Fund is subject to Irish tax laws. This may have an impact on your personal tax position. For further details, please speak to your tax adviser.
- Liability statement: Three Rock Capital Management Limited may be held liable solely on the basis of any statement contained in this document that is misleading, inaccurate or inconsistent with the relevant parts of the prospectus for the Fund.
- **Structure:** The Fund is a sub-fund of the ICAV, an Irish collective asset-management vehicle constituted as an umbrella fund with segregated liability between sub-funds. This means, subject to applicable Irish laws, that the investments of the Fund cannot be used to pay the debts of the other sub-funds of the ICAV. However, these provisions have not been tested in other jurisdictions. The Prospectus and periodic reports are prepared for the entire ICAV.
- **Switches:** Subject to the conditions set down in the Prospectus, you are entitled to switch from one or more class to another either in the Fund or another sub-fund of the ICAV. Please refer to the Prospectus and Fund Supplement for further details.
- Remuneration: Details of the up-to-date remuneration policy of the Manager, including, but not limited to, a description of how remuneration and benefits are calculated, the identity of persons responsible for awarding the remuneration and benefits including the composition of the remuneration committee, if any, are available at www.threerockcapital.com. A paper copy of the remuneration policy will be made available free of charge upon request from the Manager.

The Fund is authorised in Ireland and regulated by the Central Bank of Ireland (the "Central Bank"). Three Rock Capital Management Limited is authorised in Ireland and regulated by the Central Bank. This key investor information is accurate as at 13 February 2024.